Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
20 participants
INTERVENTIONAL
2024-01-05
2024-07-04
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
U-LABA/ICS Effects on Exercise Performance, Vilanterol
NCT06066606
Pharmacokinetic Interaction Study of Glycopyrrolate and Formoterol in Healthy Volunteers
NCT01398111
Role of Lung Function for Exercise Capacity in Well-trained Individuals
NCT06077019
Pharmacokinetic Pilot Study on Budesonide/Formoterol
NCT01457716
Symptom-driven Maintenance and Reliever Treatment to Prevent Exacerbations in COPD
NCT02477397
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
CROSSOVER
BASIC_SCIENCE
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Symbicort - usual care
Participants are administered Formoterol + Budesonide from an inhaler device testing. In addition, participants are administered a placebo capsule, which is taken orally.
Symbicort
Participants are administered 54 μg Formoterol and 1920 μg Budesonide
Formoterol - inhalation
Participants are administered Formoterol from an inhaler device testing. In addition, participants are administered a placebo capsule, which is taken orally.
Formoterol
Participants are administered 54 μg Formoterol from an inhaler device
Formoterol - oral
Participants are administered a Formoterol capsule, which is taken orally. In addition, participants are administered placebo from an inhaler device.
Formoterol
Participants are administered 120 μg Formoterol in a capsule, which is taken orally
Placebo
Participants are administered placebo from an inhaler device testing and a placebo capsule.
Placebo
Participants are administered placebo
Mannitol-test
Participants are administered Bronchitol from an inhaler device testing.
Mannitol
Participants are administered 600 mg Bronchitol
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Symbicort
Participants are administered 54 μg Formoterol and 1920 μg Budesonide
Formoterol
Participants are administered 54 μg Formoterol from an inhaler device
Formoterol
Participants are administered 120 μg Formoterol in a capsule, which is taken orally
Placebo
Participants are administered placebo
Mannitol
Participants are administered 600 mg Bronchitol
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Physically active \>5 hours a week
* Maximum oxygen uptake classified as high or very high
Exclusion Criteria
* ECG abnormality
* FEV1/FVC ratio \< 0,7 determined with spirometry
* Chronic illness determined to be a potential risk for participant during the study
* In chronic treatments with medication that may interfere with study results
* Pregnancy
* Smoker
* Blood donation during the past 3 months
18 Years
45 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Morten Hostrup, PhD
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Morten Hostrup, PhD
Associate Professor
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Morten Hostrup, PhD
Role: PRINCIPAL_INVESTIGATOR
University of Copenhagen
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
August Krogh Building
Copenhagen, , Denmark
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
FOR
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.